{"protocolSection":{"identificationModule":{"nctId":"NCT01855139","orgStudyIdInfo":{"id":"16851"},"secondaryIdInfos":[{"id":"XA1313BE","type":"OTHER","domain":"Company internal"}],"organization":{"fullName":"Bayer","class":"INDUSTRY"},"briefTitle":"Belgian Real Life Non-interventional Study (NIS) on Xarelto in Non-valvular Atrial Fibrillation (AF) Patients Treated for the Prevention of Stroke and Systemic Embolism","officialTitle":"Belgian Real Life Non-interventional Study (NIS) on Xarelto® in Non-valvular Atrial Fibrillation (AF) Patients Treated for the Prevention of Stroke and Systemic Embolism (BOX-AF)","acronym":"BOX-AF"},"statusModule":{"statusVerifiedDate":"2017-01","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2013-07"},"primaryCompletionDateStruct":{"date":"2014-10","type":"ACTUAL"},"completionDateStruct":{"date":"2014-12","type":"ACTUAL"},"studyFirstSubmitDate":"2013-05-14","studyFirstSubmitQcDate":"2013-05-14","studyFirstPostDateStruct":{"date":"2013-05-16","type":"ESTIMATED"},"lastUpdateSubmitDate":"2017-01-17","lastUpdatePostDateStruct":{"date":"2017-01-18","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Bayer","class":"INDUSTRY"},"collaborators":[{"name":"Janssen Scientific Affairs, LLC","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"The objective of this NIS is to assess in a real-life setting, usage patterns and associated outcomes in the management (healthcare resource utilisation and associated costs) of patients with non-valvular AF treated with Xarelto, in accordance with the terms of the European marketing authorization and the Belgian reimbursement criteria."},"conditionsModule":{"conditions":["Atrial Fibrillation"],"keywords":["Non-valvular atrial fibrillation","Stroke","Systemic embolism","Oral anticoagulation","Real-life setting","Preventive measure"]},"designModule":{"studyType":"OBSERVATIONAL","designInfo":{"observationalModel":"COHORT","timePerspective":"PROSPECTIVE"},"enrollmentInfo":{"count":106,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Rivaroxaban","interventionNames":["Drug: Rivaroxaban (Xarelto, BAY59-7939)"]}],"interventions":[{"type":"DRUG","name":"Rivaroxaban (Xarelto, BAY59-7939)","description":"15 mg OD or 20 mg OD","armGroupLabels":["Rivaroxaban"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of patients with major bleedings","timeFrame":"1 year or 30 days after end of rivaroxaban"},{"measure":"Number of patients with symptomatic thromboembolic events","timeFrame":"1 year or 30 days after end of rivaroxaban"},{"measure":"All-cause mortality","timeFrame":"1 year or 30 days after end of rivaroxaban"},{"measure":"Adverse events","timeFrame":"1 year or 30 days after end of rivaroxaban"},{"measure":"Treatment satisfaction measured by means of Anti-clot treatment scale (ACTS)","timeFrame":"1 year or 30 days after end of rivaroxaban"},{"measure":"Quantities of resource use consumption","timeFrame":"1 year or 30 days after end of rivaroxaban"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Adult patients ≥ 18 years old with a confirmed diagnosis of non-valvular atrial fibrillation\n* Patients must in addition present with at least one of following risk factors:\n\n  * prior stroke, TIA (transient ischemic attack) or non-CNS (central nervous system) systemic embolism\n  * left ventricular ejection fraction of \\< 40%\n  * symptomatic heart failure, New York Heart Association class 2 or higher\n  * age ≥75 years\n  * age ≥65 years in combination with either diabetes, coronary disease or arterial hypertension\n\nExclusion Criteria:\n\n* Patients who do not fulfil the Belgian reimbursement criteria","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"],"studyPopulation":"Ambulatory or hospitalized patients coming from the cardiology clinic of the participating hospitals","samplingMethod":"NON_PROBABILITY_SAMPLE"},"contactsLocationsModule":{"overallOfficials":[{"name":"Bayer Study Director","affiliation":"Bayer","role":"STUDY_DIRECTOR"}],"locations":[{"city":"Many locations","country":"Belgium"}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000001281","term":"Atrial Fibrillation"},{"id":"D000004617","term":"Embolism"}],"ancestors":[{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000001145","term":"Arrhythmias, Cardiac"},{"id":"D000006331","term":"Heart Diseases"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000016769","term":"Embolism and Thrombosis"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M7474","name":"Embolism","asFound":"Embolism","relevance":"HIGH"},{"id":"M4276","name":"Atrial Fibrillation","asFound":"Atrial Fibrillation","relevance":"HIGH"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M4143","name":"Arrhythmias, Cardiac","relevance":"LOW"},{"id":"M9109","name":"Heart Diseases","relevance":"LOW"},{"id":"M16376","name":"Thrombosis","relevance":"LOW"},{"id":"M18818","name":"Embolism and Thrombosis","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"D000069552","term":"Rivaroxaban"}],"ancestors":[{"id":"D000065427","term":"Factor Xa Inhibitors"},{"id":"D000000991","term":"Antithrombins"},{"id":"D000015842","term":"Serine Proteinase Inhibitors"},{"id":"D000011480","term":"Protease Inhibitors"},{"id":"D000004791","term":"Enzyme Inhibitors"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000000925","term":"Anticoagulants"}],"browseLeaves":[{"id":"M463","name":"Rivaroxaban","asFound":"Weight loss","relevance":"HIGH"},{"id":"M30203","name":"Factor Xa Inhibitors","relevance":"LOW"},{"id":"M3997","name":"Antithrombins","relevance":"LOW"},{"id":"M3996","name":"Antithrombin III","relevance":"LOW"},{"id":"M14033","name":"Protease Inhibitors","relevance":"LOW"},{"id":"M18081","name":"Serine Proteinase Inhibitors","relevance":"LOW"},{"id":"M19299","name":"HIV Protease Inhibitors","relevance":"LOW"},{"id":"M7641","name":"Enzyme Inhibitors","relevance":"LOW"},{"id":"M3934","name":"Anticoagulants","relevance":"LOW"},{"id":"T18","name":"Serine","relevance":"LOW"}],"browseBranches":[{"abbrev":"AnCoag","name":"Anticoagulants"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"Infe","name":"Anti-Infective Agents"},{"abbrev":"AA","name":"Amino Acids"}]}},"hasResults":false}